Skip to main content

Table 6 Changes in various parameters in patients with HbA1c at baseline of ≥7.0%

From: Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study

Parameters Dapagliflozin group Metformin group P value
Urinary 8-OHdG/creatinine (ng/mg Cre)
 Baseline 4.3 ± 1.7 (13) 4.4 ± 2.0 (17) 0.88
 Week 16 4.1 ± 1.1 (13) 5.7 ± 2.4 (17) 0.021
 Change −0.2 ± 1.6 (13) 1.3 ± 2.3 (17) 0.042
 P value within group 0.66 0.031  
Red blood cell (×104/μL)
 Baseline 485.6 ± 32.2 (13) 463.5 ± 41.4 (16) 0.12
 Week 16 507.9 ± 34.8 (12) 453.4 ± 30.9 (15) <0.001
 Change 21.3 ± 13.2 (12) −14.7 ± 18.1 (15) <0.001
 P value within group <0.001 0.007  
Hemoglobin (g/dL)
 Baseline 14.9 ± 0.8 (13) 14.0 ± 1.3 (16) 0.036
 Week 16 15.6 ± 0.7 (12) 14.0 ± 1.9 (15) 0.008
 Change 0.7 ± 0.4 (12) −0.1 ± 1.3 (15) 0.030
 P value within group <0.001 0.67  
Hematocrit (%)
 Baseline 44.1 ± 2.3 (13) 41.7 ± 3.7 (16) 0.048
 Week 16 46.1 ± 2.0 (12) 40.7 ± 3.0 (15) <0.001
 Change 2.0 ± 1.3 (12) −1.4 ± 1.7 (15) <0.001
 P value within group <0.001 0.007  
Uric acid (mg/dL)
 Baseline 5.9 ± 0.8 (13) 5.0 ± 0.9 (17) 0.012
 Week 16 5.2 ± 0.6 (12) 5.3 ± 1.0 (17) 0.74
 Change −0.7 ± 0.7 (12) 0.3 ± 0.5 (17) <0.001
 P value within group 0.007 0.041  
  1. Data are mean ± standard deviation (n). P values show results for comparisons between groups by t test or Wilcoxon rank sum test. P values within groups are results of paired t test or Wilcoxon signed rank test